Oxycodone hydrochloride - Generic Drug Details

What are the generic sources for oxycodone hydrochloride and what is the scope of freedom to operate?

Oxycodone hydrochloride is the generic ingredient in five branded drugs marketed by Ani Pharms, Avanthi Inc, Dr Reddys Labs Sa, Genus Lifesciences, Lannett Co Inc, Novel Labs Inc, Abhai Llc, Alkem Labs Ltd, Ascent Pharms Inc, Aurolife Pharma Llc, Chartwell Molecular, Hibrow Hlthcare, Hikma, Pharm Assoc, Pharmobedient, Quagen, Rhodes Pharms, Specgx Llc, Vistapharm Llc, Purdue Pharma Lp, Roxane, Zyla, Actavis Elizabeth, Alvogen, Amneal Pharms, Epic Pharma Llc, Nesher Pharms, Nuvo Pharm, Strides Pharma Intl, Sun Pharm Inds Inc, and Protega Pharms, and is included in fifty-two NDAs. There are twenty-three patents protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Oxycodone hydrochloride has four hundred and eight patent family members in forty-eight countries.

There are twelve drug master file entries for oxycodone hydrochloride. Thirty-seven suppliers are listed for this compound. There are four tentative approvals for this compound.

Summary for oxycodone hydrochloride

International Patents:	408
US Patents:	23
Tradenames:	5
Applicants:	31
NDAs:	52
Drug Master File Entries:	12
Finished Product Suppliers / Packagers:	37
Raw Ingredient (Bulk) Api Vendors:	23
Clinical Trials:	630
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for oxycodone hydrochloride
What excipients (inactive ingredients) are in oxycodone hydrochloride?	oxycodone hydrochloride excipients list
DailyMed Link:	oxycodone hydrochloride at DailyMed

Recent Clinical Trials for oxycodone hydrochloride

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Baylor College of Medicine	PHASE1
Christopher D. Verrico	PHASE1
University of South Alabama	PHASE4

See all oxycodone hydrochloride clinical trials

Generic filers with tentative approvals for OXYCODONE HYDROCHLORIDE

Applicant	Application No.	Strength	Dosage Form
		80MG	TABLET, EXTENDED RELEASE; ORAL
		80MG	TABLET, EXTENDED RELEASE; ORAL
		40MG	TABLET, EXTENDED RELEASE; ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for oxycodone hydrochloride

Drug Class	Opioid Agonist
Mechanism of Action	Full Opioid Agonists

Anatomical Therapeutic Chemical (ATC) Classes for oxycodone hydrochloride

N02AA	Natural opium alkaloids
N02A	OPIOIDS
N02	ANALGESICS
N	Nervous system

Paragraph IV (Patent) Challenges for OXYCODONE HYDROCHLORIDE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
OXAYDO	Tablets	oxycodone hydrochloride	5 mg and 7.5 mg	202080	1	2012-02-07
OXYCONTIN	Extended-release Tablets	oxycodone hydrochloride	20 mg	022272	2	2010-10-29
OXYCONTIN	Extended-release Tablets	oxycodone hydrochloride	15 mg	022272	1	2010-10-28
OXYCONTIN	Extended-release Tablets	oxycodone hydrochloride	10 mg	022272	1	2010-10-25
OXYCONTIN	Extended-release Tablets	oxycodone hydrochloride	30 mg, 60 mg and 80 mg	022272	1	2010-10-18
OXYCONTIN	Extended-release Tablets	oxycodone hydrochloride	40 mg	022272	1	2010-10-04

US Patents and Regulatory Information for oxycodone hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Purdue Pharma Lp	OXYCONTIN	oxycodone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	022272-002	Apr 5, 2010		RX	Yes	No	9,073,933			Y
Purdue Pharma Lp	OXYCONTIN	oxycodone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	022272-002	Apr 5, 2010		RX	Yes	No	9,492,393
Hibrow Hlthcare	OXYCODONE HYDROCHLORIDE	oxycodone hydrochloride	SOLUTION;ORAL	209897-001	Sep 6, 2017	AA	RX	No	No

Expired US Patents for oxycodone hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Purdue Pharma Lp	OXYCONTIN	oxycodone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	022272-007	Apr 5, 2010	7,674,799
Purdue Pharma Lp	OXYCONTIN	oxycodone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	022272-006	Apr 5, 2010	7,674,800
Zyla	OXAYDO	oxycodone hydrochloride	TABLET;ORAL	202080-001	Jun 17, 2011	8,409,616

International Patents for oxycodone hydrochloride

Country	Patent Number	Title	Estimated Expiration
Cyprus	1111487
Hong Kong	1165317	PHARMACEUTICAL DOSAGE FORMS
Argentina	103463	FORMAS DE DOSIFICACIÓN FARMACÉUTICA

Supplementary Protection Certificates for oxycodone hydrochloride

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1685839	92292	Luxembourg		PRODUCT NAME: COMBINAISON D OXYCODONE EN TANT QUE COMPOSANT A ET DE NALOXONE EN TANT QUE COMPOSANT B SOUS TOUTES LES FORMES PROTEGES PAR LE BREVET DE BASE

Market Dynamics and Financial Trajectory of Oxycodone Hydrochloride

Last updated: January 9, 2026

Executive Summary

Oxycodone Hydrochloride, a potent opioid analgesic, commands a significant position within the global pharmaceutical landscape due to its efficacy in pain management. Despite its therapeutic importance, the market faces challenges stemming from regulatory scrutiny, abuse potential, and shifting public health policies. This comprehensive analysis explores the current market dynamics, financial trajectories, key players, regulatory environment, and future outlook, providing stakeholders with a strategic understanding of this high-value drug.

---

Introduction

Oxycodone Hydrochloride is a semi-synthetic opioid derived from thebaine, primarily used for moderate to severe pain relief. It is available both as immediate-release and controlled-release formulations, notably marketed under brand names like OxyContin [1].

With a market value estimated at USD 8.4 billion in 2022, the drug's growth trajectory remains strong, driven by aging populations, rising chronic pain conditions, and expanding access in emerging markets. However, the ongoing opioid crisis and stringent regulations significantly influence supply chains, pricing strategies, and market accessibility.

---

Market Dynamics

Global Market Size and Growth Trends

Parameter	2020	2021	2022	CAGR (2022-2030)
Market Value (USD billion)	7.1	7.9	8.4	6.2%

• Key Factors Fueling Market Growth:

  • Increasing prevalence of chronic pain conditions globally [2].
  • Growing acceptance of opioid analgesics for pain management.
  • Development of novel formulations enhancing bioavailability and reducing abuse potential.

• Market Segmentation:

  • By Formulation: Immediate-release, controlled-release.
  • By Application: Chronic pain, post-surgical pain, cancer pain.
  • By Distribution Channel: Hospitals, retail pharmacies, online pharmacies.

Regional Market Distribution

Region	Market Share (2022)	Key Drivers	Challenges
North America	55%	High opioid utilization, extensive healthcare infrastructure	Regulatory scrutiny, abuse concerns
Europe	20%	Aging population, pain management protocols	Stringent prescribing guidelines
Asia-Pacific	15%	Increasing healthcare expenditure, expanding access	Regulatory hurdles, supply chain complexities
Rest of World	10%	Emerging markets, local manufacturing	Limited healthcare infrastructure

Regulatory and Policy Influences

• The US Food and Drug Administration (FDA) and Drug Enforcement Administration (DEA) impose stringent controls over opioids, impacting manufacturing and dispensing practices [3].
• International Narcotics Control Board (INCB) monitors global distribution, with crackdowns on illicit trafficking influencing legitimate markets.

---

Financial Trajectory and Market Players

Key Revenue Sources

Supplier	Market Share (Estimated 2022)	Notable Products	Revenue (USD billion)	Strategic Moves
Purdue Pharma	~20%	OxyContin	1.68	Market expansion, reformulation efforts
Teva Pharmaceutical	~18%	Generic oxycodone formulations	1.51	Cost leadership, global reach
Janssen Pharmaceuticals	~15%	Oxycodone with naloxone (Nucynta ER)	1.26	Abuse-deterrent formulations
Other Generics	~47%	Various	Remaining	Competitive pricing

Note: Purdue Pharma filed for bankruptcy in 2021 due to litigation; market share estimates adjusted accordingly.

Pricing Trends

Year	Average Price per 10 mg Oxycodone (USD)	Key Factors
2020	0.50	High competition, generic prevalence
2022	0.45	Price erosion, regulatory pressures

Prices are subject to regional variations and formulary negotiations.

Profitability and Revenue Projections

• 2018-2022: Compound annual growth rate (CAGR) of ~6%, driven by increased demand.
• Projected 2023-2030: Continued growth at a CAGR of approximately 6.2%, with revenue potential reaching USD 12.5 billion by 2030.

---

Regulatory Environment and Impact on Market Trajectory

Global Regulatory Landscape

Region	Regulations	Impact on Market	Notable Policies
USA	Strict DEA scheduling (Schedule II)	Supply constraints, increased compliance costs	Rescheduling, prescription monitoring programs (PDMPs)
Europe	Varies by country; controlled via national laws	Prescribing restrictions	European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) guidelines
Asia-Pacific	Emerging regulatory frameworks	Supply chain uncertainties	Local manufacturing and licensing requirements

Litigation and Ethical Considerations

• The US opioid epidemic led to numerous lawsuits against manufacturers, leading to significant financial liabilities and reformulation strategies emphasizing abuse-deterrent formulations [4].

Emerging Trends

• Shift towards abuse-deterrent formulations (ADFs): Oxycodone CR with abuse-deterrent features increases R&D investments.
• Policy shifts promoting alternative pain management modalities (e.g., non-opioid analgesics, cannabinoids) could temper growth.

---

Competitive Landscape and Innovation

Company	Strategic Focus	Recent Innovations	R&D Investment (USD millions)	Market Position
Purdue Pharma	Abuse-deterrent formulations	Reformulated OxyContin	150	Market leader (reduced post-bankruptcy)
Teva	Generics	Bioequivalent formulations	80	Largest generic supplier
Janssen	Branded formulations	Nucynta ER, abuse deterrence	120	Focus on specific indications
Others	Niche markets	Combined formulations	Varies	Growing generic penetration

Research & Development Outlook

• Focus on non-addictive analgesics in pipeline.
• Formulation innovations for controlled release and reduced abuse risk.
• Investments in biologics and adjunct therapies.

---

Future Outlook and Market Drivers

Growth Catalysts

• Aging demographic globally.
• Increase in surgical procedures requiring pain management.
• Expansion in emerging markets with rising healthcare access.
• Advances in formulation technology reducing abuse risks.

Challenges

• Regulatory tightening.
• Growing public and political pressure to curb opioid use.
• Emergence of alternative therapies.

Opportunities

Opportunity	Description	Potential Impact
Abuse-deterrent formulations	Development of tamper-resistant products	Market differentiation, regulatory approval
Digital health integration	Prescription monitoring, compliance apps	Market expansion, reduced misuse
New delivery systems	Transdermal patches, implantable devices	Improved patient adherence

---

Comparison with Other Opioid Analogs

Parameter	Oxycodone Hydrochloride	Morphine Sulfate	Fentanyl	Hydrocodone
Potency	1.5x Morphine	Baseline	80-100x Morphine	1x Morphine
Regulatory Control	Schedule II	Schedule II	Schedule II	Schedule II
Abuse Potential	High	High	Very high	High
Market Size (2022 USD billion)	8.4	5.2	4.9	3.5

Note: Fentanyl is primarily used in formulations for intravenous, patch, and lozenges.

---

Key Takeaways

• The Oxycodone Hydrochloride market exhibits sustained growth driven by demand for effective pain management and demographic changes, projected to reach USD 12.5 billion by 2030.
• Regulatory pressures and the opioid crisis substantially influence manufacturing, distribution, and product development strategies.
• Industry consolidation and technological innovation, especially in abuse-deterrent formulations, shape competitive dynamics.
• The emergence of non-opioid alternatives and public health policies might moderate future growth trajectories but also open avenues for innovative therapies.
• Major players focus on reformulation, global market expansion, and digital integration to sustain profitability amidst stringent regulations.

---

FAQs

1. What are the primary factors influencing the pricing of Oxycodone Hydrochloride?

Pricing is affected by generic competition, regulatory restrictions, manufacturing costs, and demand-supply dynamics. Price erosion is common with increased generic availability, while regulatory compliance costs may offset competitive pricing benefits.

2. How has the opioid epidemic affected the global market for Oxycodone?

The epidemic has led to tighter regulations, litigation, and public scrutiny, resulting in product reformulation, increased oversight, and a shift towards abuse-deterrent formulations, impacting supply and pricing.

3. What are the key regulatory hurdles for new formulations of Oxycodone?

Regulators demand comprehensive abuse-deterrence testing, safety profiles, and efficacy data. Post-approval, monitoring for misuse and diversion is stringent, affecting time-to-market.

4. What role do generic manufacturers play in the Oxycodone market?

They dominate the supply chain, offering cost-effective options, capturing significant market share, and driving price competition. Their role is crucial in meeting rising demand globally.

5. What emerging therapies could impact the future demand for Oxycodone?

Non-opioid analgesics, cannabinoids, nerve blocks, and neuromodulation techniques represent potential alternatives that could reduce reliance on opioids.

---

References

[1] U.S. Food and Drug Administration. (2022). Oxycodone Hydrochloride Summary.
[2] World Health Organization. (2021). Global Pain Management Report.
[3] U.S. DEA. (2022). Controlled Substance Schedules and Regulations.
[4] Massachusetts Attorney General. (2021). Opioid Litigation and Industry Accountability.